The United Kingdom and the United States have agreed to a key bilateral deal that will ensure zero duties on UK drug products going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to boost spending on medicines through the National Health Service (NHS). This pledge secures that duties on these vital exports will remain at zero for a period of three years.
This deal follows earlier threats to significantly raise tariffs on patented drug products, with figures discussed up to double the cost.
"This arrangement with the United Kingdom strengthens the international landscape for innovative medicines and establishes much-needed balance to transatlantic medicine commerce," a statement said.
Commercial Importance
Drugs represent one of the UK's biggest export categories to the United States, which is easily the primary buyer for large companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of the third quarter, the UK exported medicines totaling billions to the US. This amount accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal protects employment, boosts capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," a government official remarked.
Specific NHS Changes
The agreement involves several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to raise overall NHS spending on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. In the past, repayments topped 20%.
Industry Background
The deal follows a long-running dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were exacerbated by assertions that US customers were paying a premium for the same drugs than patients in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been halted or scrapped, while substantial funding commitments have been announced toward projects in the United States.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
